Patient description: The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Solid Tumor, Adult Written informed consent must be obtained prior to any clinical trial procedures 2. Aged 18 years or over. 3. Must have a pathologically documented solid tumor(s) that has relapsed from, or is refractory to standard treatment, or unable to tolerate toxicities from the SOC/available treatments, or for which no standard treatment is available. 4. Must have at least one measurable lesion as defined by for solid tumors. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 6. Life expectancy ≥3 months (as judged by the Investigator). 7. Must have adequate hematologic function (no blood transfusion and growth factor support for ≥14 days), adequate hepatic and renal function, and some key lab test results meeting the following laboratory values within 7 (+/-2) days before first dosing. 8. Must have the willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures  Have biological, chemotherapy, immunotherapy or radiotherapy less than 4 weeks prior to starting the study treatment. 2. Have undergone or plan to have major surgery (except for tumor biopsy) or experienced severe trauma ≤28 days prior to starting the study treatment. 3. Have active central nervous system lesion (i.e., imaging instability and neurologically unstable). Note: patients who have received stereotactic radiotherapy or surgical treatment for brain tumor can be included after 3 months of procedure without symptoms. 4. Previous or history of second malignancy within 3 years prior to study treatment except for curatively treated. 5. Prior therapy with MEK-inhibitor with severe toxicity causing permanent damage from it, such as ocular, cardiac, pulmonary, etc. disorders and illness. 6. History of any of the following within 6 months prior to Screening Myocardial infarction Unstable angina Coronary artery bypass graft Coronary angioplasty or stenting Chronic heart failure (New York Heart Association Grade ≥2) Ventricular arrhythmias requiring continuous therapy Supraventricular arrhythmias, including atrial fibrillation, which are uncontrolled Uncontrolled hypertension despite optimal medication management (per Investigator's assessment) Cerebrovascular accidents including transient ischemic attack, or pulmonary embolism